Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
Liang JinKai ChenCui TanJianbin LiJiayue LuoYaping YangYudong LiShunying LiLiling ZhuYue HuFengtao LiuQiuting YouMin PengZefei JiangQiang LiuPublished in: The oncologist (2020)
The modified IHC4 (mIHC4) score is easy to implement and able to predict patients with advanced and/or metastatic breast cancer. In addition, with the help of the mIHC4 score, physicians might be able to recommend chemotherapy or endocrine therapy as the first-line treatment for patients with high and low risk as predicted by the mIHC4 score.